Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Int Wound J ; 17(2): 317-325, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31850679

ABSTRACT

Human skin fibroblast (HSF) cells were irradiated with different energy lasers to detect cell proliferation, apoptosis, and expression of microRNA-206 and protein, and to further summarise the therapeutic effect of laser on scar cells. Human scar cell line HSF cells were cultured in three groups. The control group was not irradiated by laser, the low-energy group was irradiated by 10 J/cm2 laser, and the high-energy group was irradiated by 20 J/cm2 laser. After irradiation, HSF cells were cultured for 20 hours. Cell proliferation was detected by MTT assay. Cell cycle and apoptosis were detected by flow cytometry. Transwell migration assay was used to detect cell migratory ability. Reverse transcription polymerase chain reaction (RT-PCR) was used to detect miR-206 and mTOR gene levels. The levels of MMP-9, Bax, Bcl-2, cyclin D1, and mTOR signalling pathway proteins were detected by Western blotting assays. The results showed that after laser irradiation, the proliferation of cells decreased, and the difference between the control group and the experimental group was significant (P < .05). The higher the energy was, the greater the upregulation of apoptosis was. Apoptosis and cell migration increased (P < .05). The expressions of microRNA-206, MMP-9, and Bax were upregulated, while the expressions of mTOR, Bcl-2, and cyclin D1 were downregulated. To sum up, laser irradiation can significantly inhibit the proliferation of HSF cells, affect cell cycle, and increase cell apoptosis and migratory ability.


Subject(s)
Apoptosis/radiation effects , Cicatrix/radiotherapy , Fibroblasts/pathology , Gene Expression Regulation , Low-Level Light Therapy/methods , MicroRNAs/genetics , Cell Movement/radiation effects , Cell Proliferation/radiation effects , Cells, Cultured , Cicatrix/genetics , Cicatrix/pathology , Fibroblasts/metabolism , Fibroblasts/radiation effects , Humans , MicroRNAs/biosynthesis , Signal Transduction
2.
Phytother Res ; 26(3): 369-74, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21728203

ABSTRACT

The present study investigated the neuroprotective effects of aucubin on hydrogen peroxide (H2O2)-induced apoptosis in PC12 cells. Exposure of PC12 cells to 0.25 mm H2O2 induced a leakage of lactate dehydrogenase and decreased cell viability, as shown by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. In a dose over 0.1 mm, aucubin increased PC12 cellular viability and markedly attenuated H2O2-induced apoptotic cell death. Quantitation of apoptosis by flow cytometry indicated that aucubin inhibited H2O2-induced apoptosis in PC12 cells. Nuclear damage was alleviated by aucubin, as shown by Hoechst staining. In addition, the levels of malondialdehyde were reduced and the activity of superoxide dismutase, catalase and glutathione peroxidase was augmented in these cells. These results indicated that aucubin inhibited H2O2-induced apoptosis in PC12 cells through regulation of the endogenous oxidant-antioxidant balance. Our results suggest that aucubin is a potential protective agent for the treatment of oxidative-stress-induced neurodegenerative disease.


Subject(s)
Apoptosis , Hydrogen Peroxide/adverse effects , Iridoid Glucosides/pharmacology , Animals , Antioxidants/metabolism , Catalase/metabolism , Cell Nucleus Shape , Cell Survival , Enzyme Activation , Flow Cytometry , Glutathione Peroxidase/metabolism , Hydrogen Peroxide/metabolism , L-Lactate Dehydrogenase/metabolism , Malondialdehyde/metabolism , Neuroprotective Agents/pharmacology , Oxidative Stress , PC12 Cells , Rats , Staining and Labeling , Superoxide Dismutase/metabolism
3.
Brain Res ; 1307: 158-65, 2010 Jan 11.
Article in English | MEDLINE | ID: mdl-19852947

ABSTRACT

Diabetes mellitus can cause dysfunction of the central nervous system called "diabetic encephalopathy." Although insulin and various oral drugs are used to treat diabetes, they do not completely prevent the development of diabetic encephalopathy, and novel strategies for the prevention and treatment are urgently needed. Catalpol, an iridoid glycoside, has properties of anti-inflammation, antioxidant and decreasing blood glucose level and thus has the possibility of treating diabetic encephalopathy. Therefore, the study was designed to investigate the effects of catalpol on diabetic encephalopathy in rats. A single dose of 65 mg/kg streptozotocin was injected intraperitoneally to induce diabetes. Intragastric infusion of catalpol was performed for 6 weeks with the doses of 10, 50 and 100 mg/kg, respectively. The Y-type maze test, biochemical measurement, Nissl staining and the terminal deoxynucleotidyl transferase-mediated UTP nick end labeling methods were used to evaluate the neuropathological changes and the effects of catalpol on diabetic rats. The results showed that streptozotocin-induced diabetes produced obvious neuron damage and cognitive dysfunction coupling with markedly increased oxidative stress in the brain. Long-term oral supplementation of catalpol improved neuronal injury and cognitive dysfunction by attenuating oxidative stress. The effects that catalpol could both increase the nerve growth factor concentration and decrease the blood glucose level were related with the function of defending against oxidative stress of catalpol. The study suggested that oral supplementation of catalpol might be a potential therapeutic strategy for the treatment and/or prevention of diabetic encephalopathy.


Subject(s)
Diabetic Neuropathies/diet therapy , Dietary Supplements , Glucosides/administration & dosage , Iridoids/administration & dosage , Administration, Oral , Animals , Behavior, Animal/drug effects , Blood Glucose/drug effects , Body Weight/drug effects , Catalase/metabolism , Diabetes Mellitus, Experimental/physiopathology , Diabetic Neuropathies/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay/methods , Glutathione Peroxidase/metabolism , In Situ Nick-End Labeling , Iridoid Glucosides , Lipid Peroxidation/drug effects , Male , Malondialdehyde/metabolism , Maze Learning/drug effects , Nerve Growth Factor/metabolism , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Superoxide Dismutase/metabolism , Time Factors
4.
Phytother Res ; 23(7): 980-6, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19140154

ABSTRACT

In this study, the neuroprotection of aucubin and its mechanism were evaluated in the rat model of diabetic encephalopathy. Diabetes mellitus (DM) rats were stratified by cognitive capability (CC), and assigned to four treatment groups for aucubin treatment (doses of 0, 1, 5 or 10 mg/kg aucubin), with a further two groups of non-DM rats ranked by CC as controls for aucubin (doses of 0 or 5 mg/kg aucubin). Neuroprotection was estimated by the indexes of behavior and histology. Behavioral testing was performed in a Y-maze. The surviving neurons in CA1-CA4 and subiculum (SC) of the hippocampus were counted under a microscope. In addition, the apoptotic neurons in the CA1 of the hippocampus were also examined by using TUNEL staining. In order to clarify the mechanism of aucubin's neuroprotection, the activities of endogenous antioxidants and nitric oxide synthase (NOS) together with the content of lipid peroxide in the hippocampus were assayed. The results proved that aucubin significantly reduced the content of lipid peroxide, regulated the activities of antioxidant enzymatic and decreased the activity of NOS. All these effects indicated that aucubin was a potential neuroprotective agent and its neuroprotective effects were achieved, at least in part, by promoting endogenous antioxidant enzymatic activities.


Subject(s)
Antioxidants/metabolism , Diabetes Mellitus, Experimental/complications , Glucosides/pharmacology , Iridoids/pharmacology , Neurons/drug effects , Neuroprotective Agents/pharmacology , Animals , Brain Diseases/etiology , Brain Diseases/prevention & control , Cognition Disorders/etiology , Cognition Disorders/prevention & control , Hippocampus/cytology , Iridoid Glucosides , Lipid Peroxides/metabolism , Male , Malondialdehyde/metabolism , Neurons/metabolism , Nitric Oxide Synthase/metabolism , Rats , Rats, Wistar
5.
Phytother Res ; 22(6): 740-5, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18446849

ABSTRACT

Excess production of reactive oxygen species by macrophages has been implicated in many inflammatory diseases. The present study investigated the inhibitory effect of the stem bark extract of Acanthopanax senticosus on the production of superoxide anion and hydrogen peroxide in mouse peritoneal macrophages in vitro and in vivo. Exposure of mouse peritoneal macrophages to A. senticosus extract significantly suppressed superoxide anion production induced by zymosan in a dose-dependent manner. Similarly, exposure of mouse peritoneal macrophages to A. senticosus extract significantly inhibited hydrogen peroxide production induced by phorbol 12-myristate 13-acetate (PMA) in a dose-dependent manner. Intraperitoneal administration of A. senticosus extract to KM mice reduced the ex vivo production of zymosan induced-superoxide anion and PMA-induced hydrogen peroxide by their peritoneal macrophages. Exposure to A. senticosus extract did not affect the cell viability or systemic toxicity. A. senticosus inhibited reactive oxygen species production by mouse peritoneal macrophages in vitro and in vivo and may be partly responsible for the antiinflammatory function.


Subject(s)
Eleutherococcus/chemistry , Macrophages, Peritoneal/drug effects , Plant Extracts/pharmacology , Reactive Oxygen Species/metabolism , Animals , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Female , Hydrogen Peroxide/metabolism , Injections, Intraperitoneal , Macrophages, Peritoneal/cytology , Macrophages, Peritoneal/metabolism , Mice , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Superoxides/metabolism , Tetradecanoylphorbol Acetate/administration & dosage , Tetradecanoylphorbol Acetate/pharmacology , Zymosan/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL